Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level

The use of immune checkpoint inhibitors (ICIs) has greatly impacted the field of oncology. In the context of lung cancer, the approval of pembrolizumab in non-small-cell lung cancer (NSCLC) with programmed death-ligand 1 (PD-L1) expression >50% has established a foundation for the growing list of ICI monotherapy and combination therapy options for patients with ‘driver-negative’ and treatment-naive metastatic lung cancer. To date, eight ICIs have been approved for use in NSCLC, either as monotherapy or in combination. Corrigendum to “Exploring the role of accessory biomarkers TMB, STK11, KEAP1, and KRAS in non-small-cell lung cancer: confused, but on a much higher level”: [Annals of Oncology 34 (2023) 327-332]Annals of OncologyPreviewThe author regrets that in the original publication of Fig. 1 several of the elements were misaligned. The correct figure is presented below. Full-Text PDF